hotspot -WSS

hotspot

author：knowledge 2025-08-25 15:08:48 - browse：3

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Galapagos to make CAR

hotspot

WSS

What a koala virus tells us about the human genome

Boston hospital trains restaurant workers on naloxone for overdoses

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

Vivek Ramaswamy, who's embraced Trump on the campaign trail, condemned him after Jan. 6

As H5N1 spreads in cows, experts warn against drinking raw milk

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Apple is now the first public company to be valued at $3 trillion

Ripples from Flovent's discontinuation is killing children with asthma

Psychedelics group wrestles with new pharma identity

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Virginia high school admissions case could be legal follow

The United States must get value

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UK homeowners get some respite as inflation falls by more than anticipated to a 15

knowledge

Supreme Court to hear if Covid misinformation is protected speech

US soldier in North Korean custody after crossing DMZ line

ALS treatment from Biogen, Ionis fails in study

Lilly’s weekly insulin works as well as daily products, new studies show

Abbott's new stent may help patients with peripheral artery disease

A Theranos scientist

hotspot

explore

hotspot

focus